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The study aims are to evaluate the analytical performance and the clinical results of the chemiluminescent Access
AccuTnI+ 3 immunoassay for the determination of cardiac troponin I (cTnI)with DxI 800 and Access2 platforms
and to compare the clinical results obtained with this method with those of three cTnI immunoassays, recently
introduced in the European market. The limits of blank (LoB), detection (LoD), and quantitation (LoQ) at 20%
CV and 10% CV were 4.5 ng/L and 10.9 ng/L, 17.1 and 30.4 ng/L, respectively. The results of STAT Architect high
Sensitive TnI (Abbott Diagnostics), ADVIA Centaur Troponin I Ultra (Siemens Healthcare Diagnostics), ST AIA-Pack
cTnI third generation (Tosoh Bioscience), and Access AccuTnI + 3 (Beckman Coulter Diagnostics) showed very
close correlations (R ranging from 0.901 to 0.994) in 122 samples of patients admitted to the emergency depart-
ment. However, on average there was a difference up to 2.4-fold between the method measuring the highest
(ADVIA method) and lowest cTnI values (AccuTnI + 3 method). The consensus mean values between methods
ranged from 6.2% to 29.6% in 18 quality control samples distributed in an external quality control study (cTnI
concentrations ranging from 29.3 ng/L to 1557.5 ng/L). In conclusion, the results of our analytical evaluation
concerning the AccuTnI + 3 method, using the DxI platform, are well in agreement with those suggested by the
manufacturer as well as those reported by some recent studies using the Access2 platform. Our results conﬁrm
that the AccuTnI + 3 method for the Access2 and DxI 800 platforms is a clinically usable method for cTnI
measurement.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
Cardiac troponins I (cTnI) and T (cTnT) are currently considered
the most sensitive and speciﬁc biochemical markers of myocardial
damage [1–11]. Since 2000, all international guidelines from the
year 2000 recommend that an increased concentration of cardiac
troponin should be deﬁned as a value exceeding the 99th percentile
upper reference limit (99th URL) [1–5]. Moreover, an assay impreci-
sion ≤10%, estimated by coefﬁcient of variation (CV), was also rec-
ommended for the values corresponding to the 99th URL [1–5].
Unfortunately, none of the immunoassay methods, commercially
available at the time of publication of the ﬁrst guidelines [1], was
able to full-ﬁll these quality speciﬁcations. Only in the last 10 years,
a new generation of the cTnI and cTnT immunoassays has been set
up by manufacturers in order to improve the analytical performance
in accordance with international guidelines and quality speciﬁca-
tions [9,10].
The aim of this study is to evaluate the analytical performance
and the clinical results of the Access AccuTnI + 3 method, which is
a paramagnetic particle, chemiluminescent immunoassay for the
quantitative determination of cTnI levels using the DxI 800 and Ac-
cess2 platforms. We also compare the cTnI values measured with
this new method to those obtained in our laboratory by other three
recent cTnI immunoassays in plasma samples of patients admitted
to the Emergency Department (ED), as well as to results reported
by the laboratories taking part in an external quality control (EQC)
study in Italy.
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2. Materials and methods
2.1. Assay methods
The Access AccuTnI + 3 assay is a two-site immunometric assay
(BeckmanCoulter, Inc. Brea, CA92821USA). BeckmanCoulter distributes
two different kits speciﬁc for the DxI 800 (code A98264) and Access2
(code A98143) platforms, respectively. The assays were performed in
our laboratory according to themanufacturer's instructions. Instrumen-
tation aspirates 55 μL of sample for the assay, but only 50 μL is needed
for the measurement. Monoclonal anti-cTnI antibody conjugated to al-
kaline phosphatase, binding to an epitope corresponding to the amino
acids 24–40 of the peptide chain, is added to a reaction vessel along
with a surfactant-containing buffer and sample (50 μL). After a short in-
cubation (36 s), paramagnetic particles coated with monoclonal anti-
cTnI antibody, binding to an epitope corresponding to the amino acids
41–49 of the peptide chain, are also added. The human cTnI binds to
the anti-cTnI antibody on the solid phase, while the anti-cTnI anti-
body–alkaline phosphatase conjugate reacts with different antigenic
sites on the cTnI molecules. After another short incubation in a reaction
vessel, materials bound to the solid phase are held in a magnetic ﬁeld
while unbound materials are washed away. Then, the chemilumines-
cent reagent Lumi-Phos 530 is added at 37 °C to the vessel and light
generated by the reaction is measured with a luminometer. The light
production is directly proportional to the concentration of cTnI in the
sample. The cTnI amount in the sample is determined from a stored,
multi-point calibration curve. The relationship between RLU value (Y
axis) and the cTnI concentrations (X axis) very closely approximates a
second-degree polynomial equation. For this study, several lots of re-
agents (code 337132, 426619, 434885 and 431544) and calibrators
(424474, 429710 e 433808) were used.
The limits of blank (LoB) and detection (LoD) were calculated
following the CLSI EP17-A protocol [12], using the DxI 800 platform.
The 0 calibrator of the AccuTnI + 3 method, which does not contain
cTnI, was considered as the blank of the method and it was measured
in 57 different runs, using two lots of reagents. We also estimated the
0 point of the standard calibration curve by taking into account 244
cTnI values in the range of concentration between 0 and 90 ng/L. The
LoD value was calculated following the formula: LoD = LoB + 1.645
SD [12], where SDwas estimated by the distribution of cTnI valuesmea-
sured in a samplewith a plasma concentration of 10 ng/L. The reproduc-
ibility of the AccuTnI + 3 using the DxI 800 platform was evaluated
according to the CLSI EP5-A2 protocol [13], using two heparinized
plasma samples. The imprecision proﬁle was estimated by repeatedly
measuring some heparinized plasma pools collected from healthy sub-
jects and patients with cardiovascular diseases. These pools were re-
peatedly measured (from 32 to 44 different runs) using two lots of
reagents. To calculate the limit of quantiﬁcation (LoQ), the relationship
between the error of the measurement (expressed as % CV values, Y
axis) and cTnI concentrations (X axis) was interpolated by means of a
nonlinear regression power curve.
Beckman Coulter reports in the instruction bulletin that samples can
be accurately measured within the analytical range of the assay
(i.e., from 10 to 100,000 ng/L)with the AccuTnI+ 3method, suggesting
not to dilute patient samples. We veriﬁedwhether it was possible to di-
lute 5 patient samples with cTnI concentration from 55,000 to
400,000 ng/L up to 256-fold. We obtained linear correlation coefﬁcient
R2 values ranging between 0.997 and 0.999 and CV values always
b10% with both the DxI 800 and Access2 platforms.
For between-methods comparisons, other 3 immunoassay methods
were also tested in this study: the STAT Architect high Sensitive
TnI using the Architect i1000SR platform (Abbott Diagnostics, Ref.
B3P250), the ADVIA Centaur Troponin I Ultra (Siemens Healthcare
Diagnostics, Ref. 02790309), and the ST AIA-Pack cTnI third generation
method for AIA 2000LA platform (Tosoh Bioscience, Ref. 0025215).
The analytical characteristics, as evaluated by some recent studies
[2,11,14–18], of the four cTnI immunoassay methods tested in this
study are reported in Table 1.
2.2. Experimental samples
For the evaluation of analytical performance of the AccuTnI + 3
method, cTnI concentration was measured in blood samples of patients
with cardiac disease admitted to the Heart Hospital of the Fondazione
CNR Regione Toscana G. Monasterio (Massa, Italy). In order to reduce
the volume of collected blood, cTnI was measured in the plasma re-
maining after the routine clinical analyses. Samples were collected in
polypropylene tubes with lithium heparin (heparinized plasma). Plas-
ma was obtained shortly after venipuncture by centrifugation for
10 min at room temperature (about 22 °C) and then the samples, if
not immediately assayed, were frozen and stored at−20 °C in 0.5-mL
aliquots in polypropylene tubes until assay with the DxI 800 platform.
The reproducibility of the AccuTnI + 3 method was evaluated using
two heparinized plasma samples with amean cTnI of 26.5 ng/L (sample
A) and 69.1 ng/L (sample B) around the cutoff value of the method
(i.e., 40 ng/L). The imprecision proﬁle was estimated by repeatedly
measuring 8 heparinized plasma pools with mean cTnI concentrations
ranging from 13.5 ng/L to 69.1 ng/L, collected from healthy subjects
and patients with cardiovascular diseases, also including the two plas-
ma pools used for the evaluation of the reproducibility. The dilution
tests were performed using 3 heparinized samples of patients with
myocardial infarction with cTnI concentrations ranging from
55,000 to 400,000 ng/L with both the DxI 800 and Access2 platforms.
Two samples were diluted and measured with both the DxI 800
(measured cTnI concentrations 335,420 ng/L and 412,660 ng/L)
and Access2 (measured cTnI concentrations 354,660 ng/L and
406,020 ng/L) platforms, while the third sample was diluted and
measured only with the DxI 800 platform (measured cTnI concentra-
tion 55,000 ng/L).
For the between methods comparison, we used heparinized plas-
ma samples collected from 36 patients with thoracic pain (27 pa-
tients) or supraventricular tachyarrhythmias (9 patients) admitted
to the emergency department (ED) of the City Hospital of Alessan-
dria between June and November 2014. The measurement of cTnI
was performed in 122 heparinized plasma samples, collected from
these patients at the admission to ED and then 3, 6, 12 and 24 h
after. In 17 (of 27) patients admitted with thoracic pain to ED, the
clinical diagnosis was acute myocardial infarction (10 STEMI and 7
NSTEMI).
For the EQC study, 18 study samples with different cTnI concentra-
tions were prepared according to the ILAC G13 guidelines, and mea-
sured by all participant laboratories (on average 110 laboratories for
each annual cycle) for a total of 941 determinations for the 18 control
samples distributed in the annual 2014 and 2015 cycles (Table 2).
Some of these samples were repeatedly assayed by all laboratories to
test the within-laboratory variability, too. Sample pools were prepared
using residuals from heparinized plasma samples collected from
patients with cardiac diseases. For the preparation of study samples,
several heparinized plasma specimens, containing different cTnI
Table 1
Limit of detection (LoD), limit of quantiﬁcation (LoQ) at 10% and 20% CV, and 99th upper
limit of reference population of cTnI immunoassaymethods tested in this study, according
to the data reported by previous peer review studies [2,11,14–18].
Methods LoD
(ng/L)
LoQ 10% CV
(ng/L)
LoQ 20% CV
(ng/L)
99th percentile
(ng/L)
References
cTnI ADVIA 6 30–64 – 13–87 [2,11,14]
cTnI DxI 8 20 9 25 [15,16]
cTnI AIA 8.7 100 30 33 [17]
cTnI Architect 1.1–1.9 5.6 2.2 19.3 [18]
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concentrations, were pooled together (about 30–50 patients for each
pool) to obtain sample pools with a ﬁnal volume of about 100 mL.
After the preparation, the pools were immediately stored at −20 °C.
All samples were tested for the absence of HBsAg, antiHCV, and antiHIV.
Patients gave the informed consensus for the use of their residual blood
samples in the study. Information concerning the 18 study samples was
reported in Table 2.
Control study samples were sent by mail as lyophilized materials.
Lyophilization procedurewas performedby Polymed (Sambuca, Firenze,
Italy)within twoweeks after preparation of sample pools. Stored sample
pools, were thawed, then distributed in approximately 150 vials (each
containing a plasma/serum volume of 0.5 mL), and ﬁnally lyophilized,
as previously reported [19]. The lyophilizedmaterialswere reconstituted
with 0.5 mL of distilled water by participant laboratories before the
assay.
3. Statistical analysis
For the evaluation and comparison of the analytical performance
of tested cTnI immunoassay methods, standard statistical analyses
were carried on using the Stat-View 5.0.1 program (1992–98, SAS In-
stitute Inc., SAS Campus Drive, Cary, NC, USA). Because cTnI circulat-
ing levels are not normally distributed, both non-parametric tests
and parametric tests after logarithmic transformation of data were
used for statistical analysis. Statistical analyses of the collected re-
sults were computed by the reference laboratory (i.e., Department
of Laboratory Medicine, Fondazione Regione Toscana G. Monasterio,
Pisa).
For the EQC study, periodic and cumulative reports were pre-
pared and sent by mail to each participant laboratory by the
QualiMedLab, spin-off of the CNR Institute of Clinical Physiology
(Pisa, Italy), as previously described in detail [19]. It was also possi-
ble for the participant laboratories to ﬁnd their individual results and
the periodic and cumulative reports in a speciﬁc web site using a
personal password (http://www.ifc.cnr.it/eqas/). Total variability was
estimated by averaging the CVs computed from the results of each
study sample [19]. This variability includes both systematic between-
methods differences and differences introduced by the laboratories.
The imprecision of the methods was estimated by averaging the CVs of
the results produced by participants (using the same method) for the
same study sample.
4. Results
4.1. Evaluation of the analytical performance of the AccuTnI + 3 method
In Table 3, we reported the LoQ, LoD and LoQ values assessed in the
present study, using the DxI 800 platform according to the CLSI EP17-A
protocol [12], and, for comparison, those reported by the manufacturer
and in two peer review articles [15,16]. The data reported in this table
indicate that estimated values found in the present study are similar
to those reported by the manufacturer, as well as by two peer review
articles, in which the Access2 platform was used instead of the DxI
800 platform [15,16]. It is noteworthy that the LoQ value at 10 CV%
was not reported by both manufacturer and previous studies [15,16].
The results of reproducibility evaluation for the AccuTnI + 3 using the
DxI 800 platformaccording to the CLSI EP5-A2 protocol [13] are reported
in Table 4.
4.2. Between methods comparison
In Table 5 (part A), we reported the correlation matrix between the
cTnI values measured with the four cTnI methods tested in the 122
plasma samples collected from 36 patients. Very close correlations
were obtained between the results of different methods with correla-
tion coefﬁcient R ranging from 0.937 to 0.994. When we added to
these data the results obtained in the 18 control samples distributed
in the EQC study, the correlation coefﬁcients did not signiﬁcantly vary
(Table 5 part B).
However, signiﬁcant systematic differences between the cTnI
methods were observed when the 122 samples of patients were taken
into account (Fig. 1). In particular, on average, there was a difference
up to 2.4-fold between the method measuring the highest cTnI values
(ADVIA method using Centaur platform, mean cTnI 8310 ng/L) and
that measuring the lowest values (AccuTnI + 3 method using the DxI
platform, mean cTnI 3535 ng/L) (Fig. 1). As far as only the results of 18
quality control samples were considered, the differences between
methods were less signiﬁcant: in particular, there were no signiﬁcant
differences between the results observed with the AIA and Architect
platforms and also between the ADVIA method using the Centaur
platform and AccuTnI + 3 method (Fig. 2). Moreover, the varability of
the consensus mean values between methods ranged from 6.2% to
29.6% (mean ± SD = 22.7 ± 5.6%), without a signiﬁcant variation
throughout all the range of cTnI concentrations from 29.3 ng/L to
1557.5 ng/L (Table 2).
Table 2
cTnI concentrationsmeasuredwith the four immunoassaymethods by laboratories taking
part to the EQC study organized by QualiMedLab in the 2014 and 2015 cycles.
Samples DxI
(ng/L)
ADVIA
(ng/L)
AIA
(ng/L)
Architect
(ng/L)
Mean
(ng/L)
CV (%)
1 24 25 35 33 29.3 19.0
2 31 32 28 32 30.8 6.2
3 48 56 56 71 57.8 16.6
4 58 50 72 88 67.0 24.9
5 59 56 73 94 70.5 24.6
6 89 98 116 148 112.8 23.1
7 96 84 119 151 112.5 26.2
8 99 96 143 160 124.5 23.7
9 113 92 133 147 121.3 19.8
10 106 178 210 197 172.8 26.9
11 126 154 202 232 178.5 26.6
12 125 163 222 236 186.5 27.8
13 126 167 227 235 188.8 27.4
14 142 162 222 242 192.0 24.8
15 420 585 585 615 551.3 16.1
16 495 787 1068 883 808.3 29.6
17 1097 1016 1432 1682 1306.8 23.6
18 1252 1469 1494 2015 1557.5 20.8
Results
(% of total)
331
(34.8%)
241
(25.3%)
200
(21.0%)
179
(18.8%)
951
(100%)
Table 3
Analytical sensitivity parameters of theAccuTnI+3method for cTnI assay, as evaluated in the
present study using the DxI 800 platform, compared to those reported by the manufacturer
and a previous study [19].
LoB, ng/L LoD, ng/L LoQ 20 CV% LoQ 10 CV%
4.5 10.9 17.1 30.4 Present study⁎
– b10 20 – Manufacturer
5 8 20 – Previous study⁎⁎
⁎ Two lots of calibrators (433808 and 429710) and reagents (431544 and 434885)were
used on the DxI 800 platform for the calculation of analytical performance.
⁎⁎ In themulticenter studybyGreeneet al. [15] the analytical performancewas evaluated
using 42 different Access2 platforms.
Table 4
Evaluation of reproducibility of AccuTnI+3method using theDxI 800 platform according
to the CLSI EP5-A2 protocol [13].
Sample N Mean cTnI concentration
(ng/L)
Within-run
CV (%)
Total CV
(%)
A 20 26.5 10.5 13.0
B 20 69.1 2.7 3.4
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In Fig. 3, we reported the linear regressions between the cTnI
concentrations obtained with the 4 methods using log-transformation
of the original 140 values (i.e. 122 patient samples and 18 quality
controls) in order to obtain a better deﬁnition throughout all range of
cTnI concentration. These data suggest that the cTnI values measured
in the quality control samples showed the same analytical behavior of
patient samples. Moreover, the between-methods variations, expressed
as the percentage difference compared to themean concentration for the
cTnI values,measured in the EQC study [(methodA−methodB)∕mean
concentration × 100], show a linear relationship with the log-
transformation of mean cTnI concentration (DxI vs ADVIA, R = 0.652,
p b 0.0001; DxI vs Architect, R = 0.727, p b 0.0001; DxI vs AIA, R =
0.589, p b 0.0001).
Finally, a very close linear regression was found between the cTnI
valuesmeasuredwith theDxI and Access2 platforms by the laboratories
that joined to the EQC study in the 18 quality control samples (Fig. 4).
Moreover, there were no signiﬁcant differences (p = 0.3206 by paired
t test using log-transformed values) between the mean values (±SD)
respectively measured with the DxI (250.3 ± 359.2 ng/L) and Access2
(260.9 ± 385.8 ng/L) platforms.
5. Discussion
The results of this study indicate that the AccuTnI + 3 method for
cTnI assay exhibits a good reproducibility (Table 4) and a turnaround
time of less than 30-min. A very recent multicenter study [16] reported
that the 99th percentile of cTnI distribution values, measured with the
Access2 platform in 1764 apparently healthy subjects (median age 47
years, range 18–89 years), is 25 ng/L (95% CL 22–33 ng/L), with a signif-
icant difference betweenmen (31 ng/L, 95% CL 26–52 ng/L) andwomen
(21 ng/L, 95% CL 19–25 ng/L). In the instruction document, the manu-
facturer reported that the 99th percentile of cTnI distribution value is
20 ng/L (95% CL 10–50 ng/L) in a reference population, including 527
apparently healthy subjects with age raging from 19 to 94 years. The
data of the present study (Table 3) indicate that a cTnI value of about
Table 5
Correlation matrix between cTnI values measured with the four methods tested in the study.
A. Correlation matrix obtained considering the 122 samples collected from 36 patients with thoracic pain or supraventricular tachyarrhythmias admitted to the ED.
Methods ADVIA DxI AIA Architect
ADVIA 1.000 0.987 0.992 0.937
DxI 0.987 1.000 0.994 0.948
AIA 0.992 0.994 1.000 0.943
Architect 0.937 0.948 0.943 1.000
B. Correlation matrix obtained considering the 122 samples collected from patients and also the 18 quality control sample distributed in the EQC study (n = 140)
Methods ADVIA DxI AIA Architect
ADVIA 1.000 0.987 0.992 0.938
DxI 0.987 1.000 0.995 0.948
AIA 0.992 0.995 1.000 0.943
Architect 0.938 0.948 0.943 1.000
Fig. 1. Box (distribution) plot of cTnI valuesmeasured by the 4 differentmethods tested in
the study in 122heparinized plasma samples collected from36patientswith thoracic pain
or supraventricular tachyarrhythmias admitted to the ED. The data are reported as boxes
indicating the 10th, 25th, 50th (median), 75th and 90th percentiles of cTnI values measured;
thevaluesmore than90thpercentile or belowthe10thpercentilewere indicated as separated
black circles. The concentrations (Y-axis) are reported as log-scale. The levels of statistical
signiﬁcance (p values calculated by Scheffé post hoc test after ANOVA) are also indicated in
the ﬁgure. ADVIA: ADVIA method sing the Centaur platform (Siemens Health Diagnostics);
DxI: AccuTnI + 3 method using the DxI platform (Beckman Coulter Diagnostics); AIA: ST
AIA-Pack cTnI third generation method for AIA 2000LA platform (Tosoh Bioscience); ARCHI-
TECT: STAT Architect high Sensitive TnI using the Architect i1000SR platform (Abbott
Diagnostics).
Fig. 2. Box (distribution) plot of cTnI valuesmeasured in 18 quality control samples by the
4 most popular methods of the EQC study. The data are reported as boxes indicating the
10th, 25th, 50th (median), 75th and 90th percentiles of cTnI values measured in the 18
study samples; the values more than 90th percentile or below the 10th percentile were
indicated as separated black circles. The concentrations (Y-axis) are reported as log-scale.
The levels of statistical signiﬁcance (p values calculated by Scheffé post hoc test after
ANOVA) are also indicated in the ﬁgure. ADVIA: ADVIA method sing the Centaur platform
(Siemens Health Diagnostics); DxI: AccuTnI+ 3method using the DxI platform (Beckman
Coulter Diagnostics); AIA: ST AIA-Pack cTnI third generation method for AIA 2000LA plat-
form (Tosoh Bioscience); ARCHITECT: STATArchitect high Sensitive TnI using the Architect
i1000SR platform (Abbott Diagnostics).
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20 ng/L, such as the 99th percentile of cTnI distribution values in appar-
ently healthy subjects [16], should be measured by the AccuTnI + 3
method with a CV b20%. Therefore, in accordance with some recent in-
ternational guidelines and expert panel documents [2,6,9,11], the
AccuTnI + 3 method for cTnI assay should be deﬁned as a clinically ac-
ceptable contemporary sensitive assay, but not a high sensitivemethod.
The results of this study conﬁrm that there are systematic differ-
ences between the cTnI immunoassays more frequently used in Italy
(Figs. 1 and 2). In spite of these systematic differences, the cTnImethods
tested in this study showed very close linear regressions throughout all
the range of cTnI concentrations with R values ranging from 0.984 to
0.991 (Fig. 3). A very recentmulticenter study [20] evaluated the clinical
performance of the AccuTnI + 3 methods using the Access2 platform.
In 1929 subjects with chest pain or equivalent ischemic symptoms sug-
gestive of acute coronary syndromes at 14 medical centers the
AccuTnI + 3 method provided 96.0% sensitivity and 89.4% speciﬁcity
at 1–3 h after admission, and 94.9% sensitivity and 86.7% speciﬁcity at
3–6 h. The negative predictive value (NPV, rule-out for myocardial
infarction) was 99.5% at 1–3 h, and 99.0% at 3–6. Moreover, NPV was
99.1% when TnI was b0.03 ng/mL and time of symptom onset was
≥8 h [20]. Another recent study from the same group [21] indicated
that absolute delta variations of cTnI of 10 or 20 ng/L, measured with
the AccuTnI + 3methods using the Access2 platform, performed sig-
niﬁcantly better than relative delta variations (≥20% or 50%), as rec-
ommended by some international guidelines [3], for the diagnosis of
myocardial infarction at all time intervals signiﬁcantly.
This study may present some limitations. A relatively small number
of clinical samples were used for method comparison. Indeed, samples
from only 36 patients were used even if multiple samples were taken,
and the latest sample was 24 h from admission. A previous study [22]
reported different cTnI species present in sera collected at varying
time points up to 48 h after acute myocardial infarction. There is there-
fore a theoretical risk that not all different forms of cTnI may be present
in the samples of patients enrolled in this study. Another possible limi-
tation is that the use of lyophilized control material, although prepared
from patient pools, might potentially not mimic native plasma.
In conclusion, according to international guidelines [2,3], our results,
together with those reported in other very recent studies [15,16,20,21],
indicate that the cTnI AccuTnI + 3 immunoassay for the Access2 and
DxI 800 platforms is a method that may be used in the clinical practice.
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